Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks

Paul E Sax; Edwin DeJesus; Anthony Mills; Andrew Zolopa; Calvin Cohen; David Wohl; Joel E Gallant; Hui C Liu; Lijie Zhong; Kitty Yale; Kirsten White; Brian P Kearney; Javier Szwarcberg; Erin Quirk; Andrew K Cheng

doi:10.1016/s0140-6736(12)60917-9

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks

The Lancet ◽

10.1016/s0140-6736(12)60917-9 ◽

2012 ◽

Vol 379 (9835) ◽

pp. 2439-2448 ◽

Cited By ~ 311

Author(s):

Paul E Sax ◽

Edwin DeJesus ◽

Anthony Mills ◽

Andrew Zolopa ◽

Calvin Cohen ◽

...

Keyword(s):

Initial Treatment ◽

Phase 3 ◽

Double Blind ◽

Trial Analysis ◽

Analysis Of Results ◽

Hiv 1

Download Full-text

Faculty Opinions recommendation of Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717954592.793460358 ◽

2012 ◽

Author(s):

Kiat Ruxrungtham ◽

Wirach Maek-a-nantawat

Keyword(s):

Initial Treatment ◽

Phase 3 ◽

Double Blind ◽

Trial Analysis ◽

Analysis Of Results ◽

Hiv 1

Download Full-text

Faculty Opinions recommendation of Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717954439.793460355 ◽

2012 ◽

Author(s):

Kiat Ruxrungtham ◽

Wirach Maek-a-nantawat

Keyword(s):

Tenofovir Disoproxil Fumarate ◽

Initial Treatment ◽

Phase 3 ◽

Double Blind ◽

Hiv 1

Download Full-text

Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial

The Lancet ◽

10.1016/s0140-6736(17)32340-1 ◽

2017 ◽

Vol 390 (10107) ◽

pp. 2073-2082 ◽

Cited By ~ 97

Author(s):

Paul E Sax ◽

Anton Pozniak ◽

M Luisa Montes ◽

Ellen Koenig ◽

Edwin DeJesus ◽

...

Keyword(s):

Initial Treatment ◽

Phase 3 ◽

Double Blind ◽

Multicentre Phase ◽

Tenofovir Alafenamide ◽

Hiv 1

Download Full-text

Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial

The Lancet HIV ◽

10.1016/s2352-3018(19)30077-3 ◽

2019 ◽

Vol 6 (6) ◽

pp. e355-e363 ◽

Cited By ~ 27

Author(s):

David A Wohl ◽

Yazdan Yazdanpanah ◽

Axel Baumgarten ◽

Amanda Clarke ◽

Melanie A Thompson ◽

...

Keyword(s):

Initial Treatment ◽

Phase 3 ◽

Double Blind ◽

Multicentre Phase ◽

Tenofovir Alafenamide ◽

Hiv 1

Download Full-text

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial

The Lancet ◽

10.1016/s0140-6736(12)60918-0 ◽

2012 ◽

Vol 379 (9835) ◽

pp. 2429-2438 ◽

Cited By ~ 245

Author(s):

Edwin DeJesus ◽

Jürgen K Rockstroh ◽

Keith Henry ◽

Jean-Michel Molina ◽

Joseph Gathe ◽

...

Keyword(s):

Tenofovir Disoproxil Fumarate ◽

Initial Treatment ◽

Phase 3 ◽

Double Blind ◽

Hiv 1

Download Full-text

Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial

The Lancet ◽

10.1016/s0140-6736(17)32299-7 ◽

2017 ◽

Vol 390 (10107) ◽

pp. 2063-2072 ◽

Cited By ~ 107

Author(s):

Joel Gallant ◽

Adriano Lazzarin ◽

Anthony Mills ◽

Chloe Orkin ◽

Daniel Podzamczer ◽

...

Keyword(s):

Initial Treatment ◽

Phase 3 ◽

Double Blind ◽

Multicentre Phase ◽

Tenofovir Alafenamide ◽

Randomised Controlled ◽

Hiv 1

Download Full-text

Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials

The Lancet ◽

10.1016/s0140-6736(15)60616-x ◽

2015 ◽

Vol 385 (9987) ◽

pp. 2606-2615 ◽

Cited By ~ 334

Author(s):

Paul E Sax ◽

David Wohl ◽

Michael T Yin ◽

Frank Post ◽

Edwin DeJesus ◽

...

Keyword(s):

Tenofovir Disoproxil Fumarate ◽

Initial Treatment ◽

Phase 3 ◽

Double Blind ◽

Tenofovir Alafenamide ◽

Hiv 1

Download Full-text

Faculty Opinions recommendation of Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725442708.793509558 ◽

2015 ◽

Author(s):

Anthony Harries

Keyword(s):

Tenofovir Disoproxil Fumarate ◽

Initial Treatment ◽

Phase 3 ◽

Double Blind ◽

Tenofovir Alafenamide ◽

Hiv 1

Download Full-text

Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial

The Lancet HIV ◽

10.1016/s2352-3018(19)30080-3 ◽

2019 ◽

Vol 6 (6) ◽

pp. e364-e372 ◽

Cited By ~ 28

Author(s):

Hans-Jürgen Stellbrink ◽

José R Arribas ◽

Jeffrey L Stephens ◽

Helmut Albrecht ◽

Paul E Sax ◽

...

Keyword(s):

Initial Treatment ◽

Phase 3 ◽

Double Blind ◽

Multicentre Phase ◽

Tenofovir Alafenamide ◽

Hiv 1

Download Full-text

Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials

The Lancet HIV ◽

10.1016/s2352-3018(20)30099-0 ◽

2020 ◽

Vol 7 (6) ◽

pp. e389-e400 ◽

Cited By ~ 1

Author(s):

Chloe Orkin ◽

Edwin DeJesus ◽

Paul E Sax ◽

Jose R Arribas ◽

Samir K Gupta ◽

...

Keyword(s):

Initial Treatment ◽

Fixed Dose Combination ◽

Fixed Dose ◽

Phase 3 ◽

Double Blind ◽

Multicentre Phase ◽

Dose Combination ◽

Tenofovir Alafenamide ◽

Hiv 1

Download Full-text